Early intervention with azelastine nasal spray may reduce viral load in SARS-CoV-2 infected patients

Autor: Jens Peter Klussmann, Maria Grosheva, Peter Meiser, Clara Lehmann, Eszter Nagy, Valéria Szijártó, Gábor Nagy, Robert Konrat, Michael Flegel, Frank Holzer, Dorothea Groß, Charlotte Steinmetz, Barbara Scherer, Henning Gruell, Maike Schlotz, Florian Klein, Paula Aguiar de Aragão, Henning Morr, Helal Al Saleh, Andreas Bilstein, Belisa Russo, Susanne Müller-Scholtz, Cengizhan Acikel, Hacer Sahin, Nina Werkhäuser, Silke Allekotte, Ralph Mösges
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: Scientific Reports, Vol 13, Iss 1, Pp 1-12 (2023)
Druh dokumentu: article
ISSN: 2045-2322
DOI: 10.1038/s41598-023-32546-z
Popis: Abstract With the changing epidemiology of COVID-19 and its impact on our daily lives, there is still an unmet need of COVID-19 therapies treating early infections to prevent progression. The current study was a randomized, parallel, double-blind, placebo-controlled trial. Ninety SARS-CoV-2 positive patients were randomized into 3 groups receiving placebo, 0.02% or 0.1% azelastine nasal spray for 11 days, during which viral loads were assessed by quantitative PCR. Investigators assessed patients’ status throughout the trial including safety follow-ups (days 16 and 60). Symptoms were documented in patient diaries. Initial viral loads were log10 6.85 ± 1.31 (mean ± SD) copies/mL (ORF 1a/b gene). After treatment, virus load was reduced in all groups (p
Databáze: Directory of Open Access Journals
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje